COMMUNIQUÉS West-GlobeNewswire

Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
19/05/2026
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
19/05/2026
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 [...]
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
19/05/2026
– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, [...]
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment
19/05/2026
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease. SANTA ANA, Calif., May 19, 2026 ( [...]
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
19/05/2026
Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from [...]
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
19/05/2026
SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate [...]
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry Benchmarks
19/05/2026
MORRISVILLE, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- Science 37 today announced the publication of a new analysis in Applied Clinical Trials in collaboration with the Tufts Center for the Study of Drug Development (Tufts [...]
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
19/05/2026
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Zenas [...]
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
19/05/2026
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. ( [...]
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
19/05/2026
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
19/05/2026
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong [...]
XORTX Announces Closing of US$5 Million Public Offering
19/05/2026
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
19/05/2026
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") ( [...]
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
19/05/2026
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 [...]
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
19/05/2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
19/05/2026
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
19/05/2026
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or [...]
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
19/05/2026
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation [...]

Pages